Antisense modulation of phospholipid scramblase 4 expression
AssigneeIsis Pharmaceuticals, Inc.
InventorKenneth W. Dobie
Life of this patent
Estimating the term…
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of phospholipid scramblase 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phospholipid scramblase 4. Methods of using these compounds for modulation of phospholipid scramblase 4 expression and for treatment of diseases associated with expression of phospholipid scramblase 4 are provided.
Claims20
A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding phospholipid scramblase 4, wherein said compound specifically hybridizes with said nucleic acid molecule encoding phospholipid scramblase 4 and inhibits the expression of phospholipid scramblase 4.
A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding phospholipid scramblase 4.
Dependencies are inferred from the claim text.